<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048398</url>
  </required_header>
  <id_info>
    <org_study_id>REMI-001</org_study_id>
    <nct_id>NCT01048398</nct_id>
  </id_info>
  <brief_title>Remifentanil Versus Paracetamol for Pain Treatment External Cephalic Versions.</brief_title>
  <official_title>Remifentanil Versus Placebo for Pain Treatment External Cephalic Versions. Randomized, Controlled and Masked</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basque Health Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basque Health Service</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Between 3-4% of pregnancies carried to term, the fetuses are in breech
      presentation. The external version is a maneuver gynecological used to turn a breech in
      cephalic presentation. For treatment of pain suggests the use of μ agonist remifentanil for
      fast action and elimination.

      OBJECTIVE: To compare the effectiveness of remifentanil for pain management in external
      version.

      PATIENTS: Pregnant for 36 weeks or more with breech presentation who met the inclusion
      criteria and sign the consent. Participants will be randomized into two groups before the
      procedure.

      Group intervention: paracetamol and remifentanil Control group: paracetamol and placebo
      DETERMINATIONS: VAS pain level, percentage of success of the maneuver and adverse events.

      Statistical Analysis: Comparison of pain recorded by VAS in both groups and comparison of
      adverse events
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of decrease in pain experienced by patients during the maneuver according to the VAS</measure>
    <time_frame>10 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in each group in which the procedure is effective and avoids performing a Caesarean section.</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and severity</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breech Presentation</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous paracetamol 1g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.</description>
    <arm_group_label>Remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>Control group: intravenous paracetamol 1g</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>acetoaminophen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fetuses between weeks 36 and 41 of gestation confirmed by ultrasound with non-cephalic
             presentation.

          -  Informed consent signed by the mother or legal representative in his absence.

        Exclusion Criteria:

          -  Fetal anomalies

          -  Severe hypertension

          -  Allergy to drug used in the test

          -  Amniotic fluid index ≥ 5 cm

          -  Contraindication for vaginal delivery

          -  Uterine abnormality and impaired coagulation

          -  Placenta previa

          -  Rh sensitization

          -  Multiple gestation

          -  Ruptured membranes

          -  Premature detachment of normally inserted placenta

          -  The mother greater weight to 85kg
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesar A Valero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Basque Health Service</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henar Muñoz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Basque Health Service</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amanda Lopez</last_name>
    <role>Study Chair</role>
    <affiliation>Basque Health Service</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Guerra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Basque Health Service</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Echebarria, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Basque Health Service</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfonso Velasco, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Valladolid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria-Gasteiz</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>April 13, 2011</last_update_submitted>
  <last_update_submitted_qc>April 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cesar Augusto Valero Martinez</name_title>
    <organization>Hospital Txagorritxu</organization>
  </responsible_party>
  <keyword>ceophalic version</keyword>
  <keyword>breech presentation</keyword>
  <keyword>pregnancy</keyword>
  <keyword>remifentanil</keyword>
  <keyword>paracetamol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breech Presentation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

